Basar Sareyyupoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Basar Sareyyupoglu has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Pankaj Garg
Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL, USA
10 shared publications- Si Mai Pham
Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL 32224, USA
9 shared publications Mohammad Alomari
Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL, USA
7 shared publicationsKevin Landolfo
Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida
5 shared publications- Osama Haddad
Department of Cardiothoracic Surgery, Mayo Clinic Hospital , 4500 San Pablo Rd S, Jacksonville, FL, 32224
5 shared publications - Macit Bitargil
Department of Cardiovascular Surgery, Şişli Hamidiye Etfal Research and Training Hospital, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 15 (3) , 37
Outcomes of surgical tricuspid valve intervention after heart transplant
Background: Tricuspid regurgitation (TR) is common following heart transplant (HTx). Data on the outcomes of tricuspid valve (TV) surgery after HTx is limited. This study evaluates the short- and long-term outcomes of TV surgery after HTx and identifies predictors of mortality. Methods: A retrospective analysis of all HTx recipients undergoing TV surgery between 2000–2019 within the Mayo Clinic Health System was performed. Demographic, echocardiographic, hemodynamic, and postoperative outcomes were collected. Survival was estimated using Kaplan-Meier analysis, and univariable Cox regression analysis was used to identify mortality-associated risk factors. Results: Forty-one patients (mean age 53.9±14.4 years) underwent TV surgery after HTx. Biopsy-related leaflet injury (22 patients) and annular dilation (16 patients) were the most common mechanisms of TR. Nine patients underwent TV surgery during the index hospitalization of HTx, while 32 patients were operated on during follow-up. After TV surgery, 5- and 10- year survival was 60.5% and 23.5%, respectively. There were 23 deaths (5 during the index hospitalization for TV surgery, while 18 died during follow-up). Preoperative predictors of mortality were elevated right atrial pressure (RAP), right ventricular end-diastolic pressure (RVEDP), and mean pulmonary artery pressure (mPAP), and international normalized ratio (INR), along with hypoalbuminemia (PConclusions: TV surgery after HTx is associated with significant early and late mortality. In HTx recipients, TV surgery should be performed before the onset of RV dysfunction and hepatic dysfunction.
- 1 May 2026
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 15 (3) , 37
Open AccessOutcomes of surgical tricuspid valve intervention after heart transplant
Background: Tricuspid regurgitation (TR) is common following heart transplant (HTx). Data on the outcomes of tricuspid valve (TV) surgery after HTx is limited. This study evaluates the short- and long-term outcomes of TV surgery after HTx and identifies predictors of mortality. Methods: A retrospective analysis of all HTx recipients undergoing TV surgery between 2000–2019 within the Mayo Clinic Health System was performed. Demographic, echocardiographic, hemodynamic, and postoperative outcomes were collected. Survival was estimated using Kaplan-Meier analysis, and univariable Cox regression analysis was used to identify mortality-associated risk factors. Results: Forty-one patients (mean age 53.9±14.4 years) underwent TV surgery after HTx. Biopsy-related leaflet injury (22 patients) and annular dilation (16 patients) were the most common mechanisms of TR. Nine patients underwent TV surgery during the index hospitalization of HTx, while 32 patients were operated on during follow-up. After TV surgery, 5- and 10- year survival was 60.5% and 23.5%, respectively. There were 23 deaths (5 during the index hospitalization for TV surgery, while 18 died during follow-up). Preoperative predictors of mortality were elevated right atrial pressure (RAP), right ventricular end-diastolic pressure (RVEDP), and mean pulmonary artery pressure (mPAP), and international normalized ratio (INR), along with hypoalbuminemia (PConclusions: TV surgery after HTx is associated with significant early and late mortality. In HTx recipients, TV surgery should be performed before the onset of RV dysfunction and hepatic dysfunction.
- Open Access
- 28 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2637
Percutaneous Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation in the Current UNOS Allocation System
Background: Progressive heart failure cardiogenic shock (HFCS) often requires escalation to temporary or durable mechanical circulatory support (MCS) as a bridge to transplant (BTT). Following the 2018 UNOS allocation changes, our center revised its BTT strategy to optimize support and shorten wait times. At our institution, the Impella 5.5 with SmartAssist via the axillary approach was selectively used for patients who remained refractory to guideline-directed medical therapy, failed single-inotrope therapy, and were not considered suitable durable LVAD candidates by our multidisciplinary heart team. We compared transplant-related outcomes of BTT patients supported with Impella 5.5 versus durable LVAD. Methods: We performed a single-center retrospective review of all heart and heart/kidney transplant candidates at Mayo Clinic Florida from October 2018 to February 2021. INTERMACS profile, baseline characteristics, and perioperative data were collected at the time of device implantation and throughout the transplant hospitalization. Results: A total of 87 heart and 4 heart–kidney transplants were completed. Forty-five patients (49%) required MCS as BTT: 27 (60%) with a durable LVAD and 18 (40%) with an Impella 5.5. All eighteen patients with Impella 5.5 as BTT (100%) were transplanted compared to nineteen patients with durable LVAD (70%), p = 0.001. The median time from listing to transplant was substantially shorter with Impella (32 vs. 696 days, p < 0.001), and this difference persisted across INTERMACS profiles. UNOS status at transplant was more urgent for Impella than LVAD (p < 0.001). Transplant surgery following Impella support required shorter cardiopulmonary bypass time (181 vs. 219 min, p < 0.001) and resulted in lower postoperative vasoactive-inotropic requirements (7.9 vs. 13, p = 0.003). No patients in the Impella group died or were delisted while awaiting transplant, whereas 5 LVAD patients (26%) died or were removed due to LVAD complications (p < 0.001). Conclusions: Our data demonstrates that the use of the Impella 5.5 as BTT was associated with significantly shorter waitlist time, higher transplantation rates, reduced perioperative morbidity, and lower postoperative vasoactive support compared with durable LVAD as BTT. These benefits were achieved despite a higher severity of illness at transplantation in the Impella cohort.
- 28 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2637
Open AccessPercutaneous Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation in the Current UNOS Allocation System
Background: Progressive heart failure cardiogenic shock (HFCS) often requires escalation to temporary or durable mechanical circulatory support (MCS) as a bridge to transplant (BTT). Following the 2018 UNOS allocation changes, our center revised its BTT strategy to optimize support and shorten wait times. At our institution, the Impella 5.5 with SmartAssist via the axillary approach was selectively used for patients who remained refractory to guideline-directed medical therapy, failed single-inotrope therapy, and were not considered suitable durable LVAD candidates by our multidisciplinary heart team. We compared transplant-related outcomes of BTT patients supported with Impella 5.5 versus durable LVAD. Methods: We performed a single-center retrospective review of all heart and heart/kidney transplant candidates at Mayo Clinic Florida from October 2018 to February 2021. INTERMACS profile, baseline characteristics, and perioperative data were collected at the time of device implantation and throughout the transplant hospitalization. Results: A total of 87 heart and 4 heart–kidney transplants were completed. Forty-five patients (49%) required MCS as BTT: 27 (60%) with a durable LVAD and 18 (40%) with an Impella 5.5. All eighteen patients with Impella 5.5 as BTT (100%) were transplanted compared to nineteen patients with durable LVAD (70%), p = 0.001. The median time from listing to transplant was substantially shorter with Impella (32 vs. 696 days, p < 0.001), and this difference persisted across INTERMACS profiles. UNOS status at transplant was more urgent for Impella than LVAD (p < 0.001). Transplant surgery following Impella support required shorter cardiopulmonary bypass time (181 vs. 219 min, p < 0.001) and resulted in lower postoperative vasoactive-inotropic requirements (7.9 vs. 13, p = 0.003). No patients in the Impella group died or were delisted while awaiting transplant, whereas 5 LVAD patients (26%) died or were removed due to LVAD complications (p < 0.001). Conclusions: Our data demonstrates that the use of the Impella 5.5 as BTT was associated with significantly shorter waitlist time, higher transplantation rates, reduced perioperative morbidity, and lower postoperative vasoactive support compared with durable LVAD as BTT. These benefits were achieved despite a higher severity of illness at transplantation in the Impella cohort.
- Open Access
- 23 January 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-3
Utilization of ultrasonic aspirator for combined aortic and mitral valve decalcification: a case study
Mitral and aortic annular calcification is an age-related degenerative process that can result in severe mitral and/or aortic stenosis and/or regurgitation. Annular calcification not only increases the surgical complexity but also increases the risk of complications. In this case report, we present the innovative use of the Sonopet ultrasonic surgical aspirator for aortic and mitral annular decalcification in a patient with hypertrophic obstructive cardiomyopathy, mild aortic stenosis and moderate mitral regurgitation in the presence of mitral annular calcification (MAC) and aorto-mitral curtain calcification.
- 23 January 2025
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 20 (1) , 1-3
Open AccessUtilization of ultrasonic aspirator for combined aortic and mitral valve decalcification: a case study
Mitral and aortic annular calcification is an age-related degenerative process that can result in severe mitral and/or aortic stenosis and/or regurgitation. Annular calcification not only increases the surgical complexity but also increases the risk of complications. In this case report, we present the innovative use of the Sonopet ultrasonic surgical aspirator for aortic and mitral annular decalcification in a patient with hypertrophic obstructive cardiomyopathy, mild aortic stenosis and moderate mitral regurgitation in the presence of mitral annular calcification (MAC) and aorto-mitral curtain calcification.
- Open Access
- 30 July 2024
- Published by Elsevier in JTCVS Techniques
- Vol. 27, 132-134
Heart transplant for a patient with left superior vena cava: Case report and surgical technique
- 30 July 2024
- Published by Elsevier in JTCVS Techniques
- Vol. 27, 132-134
Open AccessHeart transplant for a patient with left superior vena cava: Case report and surgical technique
- Open Access
- 1 April 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (4) , rjae211
Outcome of lung transplantation in patients with pulmonary alveolar microlithiasis in the era of COVID-19 infection
Lung transplant recipients are at higher risk of developing COVID-19 infection compared to other solid organ transplants. The risk further increases in the unvaccinated patients. We present a case of a 43-year-old male who underwent bilateral sequential lung transplantation for pulmonary alveolar microlithiasis (PAM) and had an uneventful recovery. However, two years post-transplantation, the patient developed chronic lung allograft dysfunction (CLAD) with bronchiolitis obliterans syndrome and two episodes of COVID-19 infection. During the second episode of COVID-19 infection, the patient developed sepsis and multi-organ dysfunction ultimately resulting in death. Our case report highlights the increased susceptibility of PAM patients’ post-lung transplant to COVID-19 infection. Continuous follow-up of PAM patients’ post-lung transplantation is necessary to prevent unfavorable outcomes.
- 1 April 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (4) , rjae211
Open AccessOutcome of lung transplantation in patients with pulmonary alveolar microlithiasis in the era of COVID-19 infection
Lung transplant recipients are at higher risk of developing COVID-19 infection compared to other solid organ transplants. The risk further increases in the unvaccinated patients. We present a case of a 43-year-old male who underwent bilateral sequential lung transplantation for pulmonary alveolar microlithiasis (PAM) and had an uneventful recovery. However, two years post-transplantation, the patient developed chronic lung allograft dysfunction (CLAD) with bronchiolitis obliterans syndrome and two episodes of COVID-19 infection. During the second episode of COVID-19 infection, the patient developed sepsis and multi-organ dysfunction ultimately resulting in death. Our case report highlights the increased susceptibility of PAM patients’ post-lung transplant to COVID-19 infection. Continuous follow-up of PAM patients’ post-lung transplantation is necessary to prevent unfavorable outcomes.
- 23 February 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (5) , 559-566
Absorbable antibiotic beads for treatment of LVAD driveline infections
Backgound: Infections of the left ventricular assist device (LVAD) driveline are a dreaded complication that results in high mortality and morbidity.Method: We retrospectively reviewed five consecutive patients with severe continuous‐flow LVAD (HVAD, Heartmate 2, and Heartmate 3) driveline infection. These infections, which developed on an average of 960.4 ± 843.9 days after LVAD placement, were refractory to systemic antibiotics and local wound care. All were treated with extensive surgical debridement, local installation of absorbable antibiotic‐loaded calcium sulfate beads (vancomycin and tobramycin), primary wound closure, and 6 weeks of systemic antibiotics after surgery.Results: Four patients had resolution of DLI, and one had a recurrent infection at another part of the driveline 7 months after the complete resolution of the previous site. This patient was successfully treated with debridement and bead placements. Three patients still have their LVADs, while two received orthotopic heart transplants. At the time of the transplant, there was no evidence of gross infection of the LVAD drivelines or pumps. At the average follow‐up time of 425.8 ± 151 days, no patients have an active infection.Conclusion: Treatment of LVAD driveline infection with absorbable antibiotic beads with primary wound closure is a viable option and merits further investigation.
- 23 February 2024
- Published by Wiley in Artificial Organs
- Vol. 48 (5) , 559-566
Absorbable antibiotic beads for treatment of LVAD driveline infections
Backgound: Infections of the left ventricular assist device (LVAD) driveline are a dreaded complication that results in high mortality and morbidity.Method: We retrospectively reviewed five consecutive patients with severe continuous‐flow LVAD (HVAD, Heartmate 2, and Heartmate 3) driveline infection. These infections, which developed on an average of 960.4 ± 843.9 days after LVAD placement, were refractory to systemic antibiotics and local wound care. All were treated with extensive surgical debridement, local installation of absorbable antibiotic‐loaded calcium sulfate beads (vancomycin and tobramycin), primary wound closure, and 6 weeks of systemic antibiotics after surgery.Results: Four patients had resolution of DLI, and one had a recurrent infection at another part of the driveline 7 months after the complete resolution of the previous site. This patient was successfully treated with debridement and bead placements. Three patients still have their LVADs, while two received orthotopic heart transplants. At the time of the transplant, there was no evidence of gross infection of the LVAD drivelines or pumps. At the average follow‐up time of 425.8 ± 151 days, no patients have an active infection.Conclusion: Treatment of LVAD driveline infection with absorbable antibiotic beads with primary wound closure is a viable option and merits further investigation.
- Open Access
- 31 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1345540
PlasmaBlade-assisted surgical septal myectomy: technique and our experience
Background: The pulsed-electron avalanche knife (PEAK) PlasmaBlade provides an atraumatic, scalpel-like cutting precision and electrocautery-like hemostasis. PlasmaBlade operates near body temperature, and its long, thin, and malleable tip can overcome the limitations of a surgical knife. In this study, we aimed to evaluate our clinical experience and histopathological outcomes of septal myectomy using PlasmaBlade.Methods: Electronic medical records were reviewed for preoperative, operative, and follow-up data of the patients who underwent septal myectomy using PEAK PlasmaBlade at our institute between January 2019 and December 2022. Histopathology of the myectomy specimens was reviewed for the depth of muscle necrosis and compared with the left atrial appendage (LAA) specimen.Results: Twenty-nine patients underwent septal myectomy using the PEAK PlasmaBlade. No mortality was reported. The mean age was 60.6 ± 12.5 years, and 58.6% of patients were male. Peak left ventricular outflow tract (LVOT) gradients were 40.5 ± 34.9 mmHg at rest and 56.5 ± 34.9 mmHg after provocation. Concomitant procedures performed were LAA ligation in 20 (69.0%), aortic valve replacement in 5 (17.2%), and coronary artery bypass grafting in 3 (10.3%) patients. Postoperative complications were complete heart block in one (3.4%) and ventricular septal defect in two (6.9%) patients. Both the ventricular septal defects were identified intraoperatively and repaired. Histopathology of myectomy specimens demonstrated cautery artifact limited to 1,000 µm with conventional electrocautery. At a mean follow-up of 8.4 ± 10.3 months, the mean LVOT gradient was 4.4 ± 5.8 mmHg at rest and 9.5 ± 3.3 mmHg after provocation. All patients were alive and in New York Heart Association class I/II. No patient developed complications or required reintervention or reoperation.Conclusion: Adequate septal myectomy can be precisely and safely performed using the PEAK PlasmaBlade with minimal collateral damage.
- 31 January 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1345540
Open AccessPlasmaBlade-assisted surgical septal myectomy: technique and our experience
Background: The pulsed-electron avalanche knife (PEAK) PlasmaBlade provides an atraumatic, scalpel-like cutting precision and electrocautery-like hemostasis. PlasmaBlade operates near body temperature, and its long, thin, and malleable tip can overcome the limitations of a surgical knife. In this study, we aimed to evaluate our clinical experience and histopathological outcomes of septal myectomy using PlasmaBlade.Methods: Electronic medical records were reviewed for preoperative, operative, and follow-up data of the patients who underwent septal myectomy using PEAK PlasmaBlade at our institute between January 2019 and December 2022. Histopathology of the myectomy specimens was reviewed for the depth of muscle necrosis and compared with the left atrial appendage (LAA) specimen.Results: Twenty-nine patients underwent septal myectomy using the PEAK PlasmaBlade. No mortality was reported. The mean age was 60.6 ± 12.5 years, and 58.6% of patients were male. Peak left ventricular outflow tract (LVOT) gradients were 40.5 ± 34.9 mmHg at rest and 56.5 ± 34.9 mmHg after provocation. Concomitant procedures performed were LAA ligation in 20 (69.0%), aortic valve replacement in 5 (17.2%), and coronary artery bypass grafting in 3 (10.3%) patients. Postoperative complications were complete heart block in one (3.4%) and ventricular septal defect in two (6.9%) patients. Both the ventricular septal defects were identified intraoperatively and repaired. Histopathology of myectomy specimens demonstrated cautery artifact limited to 1,000 µm with conventional electrocautery. At a mean follow-up of 8.4 ± 10.3 months, the mean LVOT gradient was 4.4 ± 5.8 mmHg at rest and 9.5 ± 3.3 mmHg after provocation. All patients were alive and in New York Heart Association class I/II. No patient developed complications or required reintervention or reoperation.Conclusion: Adequate septal myectomy can be precisely and safely performed using the PEAK PlasmaBlade with minimal collateral damage.
- Open Access
- 18 September 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1237772
Case report: Heart transplant for persistent right heart failure after complete surgical repair and percutaneous closure of post-myocardial infarction ventricular septal rupture
The incidence of post-acute myocardial infarction ventricular septal rupture (post-AMI VSR) has decreased; however, mortality after surgical repair of post-AMI VSR remains high. Patients who are not surgical candidates can be managed by heart transplant with a good outcome. A heart transplant in a patient after successful repair of VSR has never been reported. We report a patient who had persistent right heart failure after the successful repair of VSR and underwent a heart transplant with a good outcome.
- 18 September 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1237772
Open AccessCase report: Heart transplant for persistent right heart failure after complete surgical repair and percutaneous closure of post-myocardial infarction ventricular septal rupture
The incidence of post-acute myocardial infarction ventricular septal rupture (post-AMI VSR) has decreased; however, mortality after surgical repair of post-AMI VSR remains high. Patients who are not surgical candidates can be managed by heart transplant with a good outcome. A heart transplant in a patient after successful repair of VSR has never been reported. We report a patient who had persistent right heart failure after the successful repair of VSR and underwent a heart transplant with a good outcome.
- Open Access
- 27 July 2023
- Published by Elsevier in JTCVS Techniques
- Vol. 22, 220-222
Septal myectomy for hypertrophic obstructive cardiomyopathy using a pulsed radiofrequency energy soft tissue dissection instrument
- 27 July 2023
- Published by Elsevier in JTCVS Techniques
- Vol. 22, 220-222
Open AccessSeptal myectomy for hypertrophic obstructive cardiomyopathy using a pulsed radiofrequency energy soft tissue dissection instrument